Brain Cancer

Oncology
6
Pipeline Programs
8
Companies
22
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
3
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
133%
Monoclonal Antibody
133%
ADC
133%
+ 4 programs with unclassified modality

Competitive Landscape

7 companies ranked by most advanced pipeline stage

E
EisaiChina - Liaoning
1 program
1
PalonosetronPhase 21 trial
Active Trials
NCT00636805Terminated63Est. Jan 2013
Genentech
GenentechCA - Oceanside
1 program
1
TemozolomidePhase 21 trial
Active Trials
NCT01105702Terminated28Est. Apr 2015
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
Trastuzumab deruxtecanPhase 2ADC1 trial
Active Trials
NCT06058988Recruiting30Est. Sep 2027
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
1
AfatinibPhase 1Small Molecule1 trial
Active Trials
NCT02423525Completed24Est. Aug 2021
M&
Merck & Co.RAHWAY, NJ
1 program
1
MK-3475Phase 15 trials
Active Trials
NCT02852655Active Not Recruiting60Est. Jan 2026
NCT02512172Completed27Est. Nov 2021
NCT02630823Completed10Est. Oct 2020
+2 more trials
GS
Gilead SciencesFOSTER CITY, CA
1 program
1
MagrolimabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT05169944Completed13Est. Sep 2024
Varian Medical Systems
1 program
Halcyon 4.0 systemN/A1 trial
Active Trials
NCT05427214CompletedEst. Oct 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
AstraZenecaTrastuzumab deruxtecan
Merck & Co.MK-3475
Merck & Co.MK-3475
GenentechTemozolomide
EisaiPalonosetron
Merck & Co.MK-3475
Merck & Co.MK-3475
Merck & Co.MK-3475
Merck & Co.MK-3475
Merck & Co.MK-3475
Merck & Co.MK-3475
Merck & Co.MK-3475
Gilead SciencesMagrolimab
Boehringer IngelheimAfatinib
Merck & Co.MK-3475

Showing 15 of 22 trials with date data

Clinical Trials (22)

Total enrollment: 1,255 patients across 22 trials

NCT06058988AstraZenecaTrastuzumab deruxtecan

Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer

Start: Sep 2023Est. completion: Sep 202730 patients
Phase 2Recruiting
NCT02296684Merck & Co.MK-3475

Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma

Start: Mar 2015Est. completion: Jul 202567 patients
Phase 2Completed
NCT01876511Merck & Co.MK-3475

Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C)

Start: Sep 2013Est. completion: Aug 2019113 patients
Phase 2Completed
NCT01105702GenentechTemozolomide

Temodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade Glioma

Start: May 2010Est. completion: Apr 201528 patients
Phase 2Terminated
NCT00636805EisaiPalonosetron

Aloxi for Prevention of Chemotherapy Induced Nausea and Vomiting in Malignant Glioma Patients Receiving Irinotecan With Bevacizumab

Start: May 2008Est. completion: Jan 201363 patients
Phase 2Terminated
NCT02535247Merck & Co.MK-3475

Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma

Start: Jan 2016Est. completion: Feb 202017 patients
Phase 1/2Terminated
NCT02311582Merck & Co.MK-3475

MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas

Start: Aug 2015Est. completion: Apr 202455 patients
Phase 1/2Completed
NCT02422381Merck & Co.MK-3475

MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)

Start: Jul 2015Est. completion: Dec 202616 patients
Phase 1/2Active Not Recruiting
NCT02348008Merck & Co.MK-3475

Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:

Start: Mar 2015Est. completion: Dec 201961 patients
Phase 1/2Completed
NCT02289222Merck & Co.MK-3475

1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma

Start: Dec 2014Est. completion: Aug 201748 patients
Phase 1/2Terminated
NCT02178722Merck & Co.MK-3475

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Start: Jul 2014Est. completion: Nov 2020444 patients
Phase 1/2Completed
NCT02430363Merck & Co.MK-3475

Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475

Start: Mar 2013Est. completion: Jun 201858 patients
Phase 1/2Unknown
NCT05169944Gilead SciencesMagrolimab

Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors

Start: Apr 2022Est. completion: Sep 202413 patients
Phase 1Completed
NCT02423525Boehringer IngelheimAfatinib

Safety Study of Afatinib for Brain Cancer

Start: Dec 2016Est. completion: Aug 202124 patients
Phase 1Completed
NCT02852655Merck & Co.MK-3475

A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma

Start: Sep 2016Est. completion: Jan 202660 patients
Phase 1Active Not Recruiting
NCT02512172Merck & Co.MK-3475

A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer

Start: Feb 2016Est. completion: Nov 202127 patients
Phase 1Completed
NCT02630823Merck & Co.MK-3475

MK-3475 Immunotherapy in Endometrial Carcinoma

Start: Feb 2016Est. completion: Oct 202010 patients
Phase 1Completed
NCT02324582Merck & Co.MK-3475

MK-3475/BCG in High Risk Superficial Bladder Cancer

Start: Jun 2015Est. completion: Mar 202318 patients
Phase 1Completed
NCT02318771Merck & Co.MK-3475

Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer

Start: Feb 2015Est. completion: Mar 202141 patients
Phase 1Completed
NCT02268825Merck & Co.MK-3475

Phase I Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers

Start: Jan 2015Est. completion: Jun 201739 patients
Phase 1Terminated
NCT02179918Merck & Co.MK-3475

A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)

Start: Aug 2014Est. completion: Feb 201723 patients
Phase 1Completed
NCT05427214Varian Medical SystemsHalcyon 4.0 system

Imaging Study on Halcyon 4.0 System for Patients Receiving Radiation Therapy

Start: Aug 2022Est. completion: Oct 2024
N/ACompleted

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1m ago

Office Administrator

SystImmune
1m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
11m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
15m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
15m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 1,255 patients
8 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)